Widmann Financial Services Inc. Sells 192 Shares of Medtronic plc (NYSE:MDT)

Widmann Financial Services Inc. lowered its holdings in shares of Medtronic plc (NYSE:MDT) by 5.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 3,157 shares of the medical technology company’s stock after selling 192 shares during the quarter. Widmann Financial Services Inc.’s holdings in Medtronic were worth $284,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Fortitude Family Office LLC purchased a new stake in Medtronic during the 3rd quarter valued at about $27,000. Darwin Wealth Management LLC bought a new stake in Medtronic in the third quarter valued at approximately $27,000. Highline Wealth Partners LLC purchased a new stake in shares of Medtronic during the third quarter valued at approximately $27,000. J. Stern & Co. LLP bought a new position in shares of Medtronic in the third quarter worth approximately $30,000. Finally, Lynx Investment Advisory purchased a new position in shares of Medtronic in the second quarter worth $28,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the subject of several analyst reports. Oppenheimer increased their price target on shares of Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. Barclays increased their target price on shares of Medtronic from $105.00 to $109.00 and gave the stock an “overweight” rating in a report on Tuesday. UBS Group upgraded Medtronic from a “sell” rating to a “neutral” rating and boosted their price target for the company from $76.00 to $90.00 in a report on Thursday, August 15th. Robert W. Baird cut their price objective on Medtronic from $96.00 to $93.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. Finally, Truist Financial boosted their target price on Medtronic from $90.00 to $93.00 and gave the company a “hold” rating in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Medtronic has an average rating of “Hold” and an average target price of $95.27.

Medtronic Trading Up 0.3 %

Shares of NYSE MDT opened at $86.54 on Friday. The stock has a market cap of $110.98 billion, a P/E ratio of 26.46, a price-to-earnings-growth ratio of 2.44 and a beta of 0.84. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.39. Medtronic plc has a 1 year low of $75.96 and a 1 year high of $92.68. The firm has a 50-day moving average of $88.69 and a 200 day moving average of $84.99.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm had revenue of $8.40 billion for the quarter, compared to analysts’ expectations of $8.27 billion. During the same period in the previous year, the firm posted $1.25 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, sell-side analysts expect that Medtronic plc will post 5.46 EPS for the current fiscal year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.